Created at	Source	Raw Value	Validated value
Dec. 11, 2022, 4 a.m.	usa	Number of Patients With Potential Effects on the Incidence of Antibody-Dependent Enhancement (ADE);Number of Patients With TEAEs;Number of Patients With Treatment-Emergent Adverse Events of Special Interest (TEAESI; Infusion Related Reactions Including Hypersensitivity/Anaphylactic Reaction);Number of Patients With Treatment-Emergent Serious Adverse Events (TESAEs)	Number of Patients With Potential Effects on the Incidence of Antibody-Dependent Enhancement (ADE);Number of Patients With TEAEs;Number of Patients With Treatment-Emergent Adverse Events of Special Interest (TEAESI; Infusion Related Reactions Including Hypersensitivity/Anaphylactic Reaction);Number of Patients With Treatment-Emergent Serious Adverse Events (TESAEs)
Nov. 22, 2022, noon	usa	None	None
April 9, 2022, 10 p.m.	usa	Number of Patients With Potential Effects on the Incidence of Antibody-Dependent Enhancement (ADE);Number of Patients With TEAEs;Number of Patients With Treatment-Emergent Adverse Events of Special Interest (TEAESI; Infusion Related Reactions Including Hypersensitivity/Anaphylactic Reaction);Number of Patients With Treatment-Emergent Serious Adverse Events (TESAEs)	Number of Patients With Potential Effects on the Incidence of Antibody-Dependent Enhancement (ADE);Number of Patients With TEAEs;Number of Patients With Treatment-Emergent Adverse Events of Special Interest (TEAESI; Infusion Related Reactions Including Hypersensitivity/Anaphylactic Reaction);Number of Patients With Treatment-Emergent Serious Adverse Events (TESAEs)
Oct. 26, 2020, 11:31 p.m.	usa	To evaluate the preliminary safety and tolerability of CT-P59 up to Day 14 of the last enrolled subject	To evaluate the preliminary safety and tolerability of CT-P59 up to Day 14 of the last enrolled subject